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Fibromyalgia	syndrome	(FMS)	is	a	
neurosensory	 disorder	 of	 unknown	
etiology	 characterized	 by	 chronic	
musculoskeletal	 pain,	 fatigue,	 ten-
derness	 and	 sleep	 disturbances.	
FMS	 can	 result	 in	 severe	 disability	
and	loss	of	function,	 leading	to	de-





giene treatment are often needed 
to	 ensure	 patient	 comfort	 and	 op-




Appropriate dental hygiene manage-
ment	 requires	 an	 understanding	 of	
disease	 characteristics	 and	 pathophysiology,	 oral	
health	considerations	and	treatment	interventions.	
Epidemiology
FMS	 is	 the	 second	 most	 common	 diagnosis	
made by rheumatologists and is estimated to af-
fect	3	to	6%	of	 the	population	worldwide.2,3	FMS	






incidence	may	 be	 increasing	 and	 is	 linked	 to	 in-
creased	disease	awareness	among	physicians.
Basic Characteristics
The	 1990	 American	 College	 of	 Rheumatology	
classification	criteria	for	FMS	included	a	history	of	
chronic,	diffuse	pain	affecting	4	quadrants	of	the	
body for at least 3 months and pain upon palpation 
in at least 11 out of 18 tender points.15	In	2010,	
the	 American	 College	 of	 Rheumatology	 revised	
this	criterion,	eliminating	the	need	to	assess	ten-




























found in Figure 1 must be met. 
The	most	predominant	symptom	of	FMS	is	chron-
ic,	widespread	musculoskeletal	pain,	described	as	
being	 persistent,	 deep,	 aching	 and/or	 throbbing.	
Hyperalgesia	(exaggerated	or	prolonged	response	










Fatigue,	 cognitive	 deficiency,	 tenderness	 upon	
mild	palpation	and	non-restorative	sleep	are	com-
mon	manifestations	often	accompanied	by	a	wide	
array of additional symptoms listed in Figure 2.20,21 
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The	onset	of	symptoms	can	appear	suddenly;	how-
ever,	they	are	generally	experienced	gradually.20,22 
Common	 psychiatric	 and	 medical	 comorbidities	
may	also	be	present	(Figure	3).18,21
Diseases	 of	 fatigue	 and	widespread	 pain	 have	














with	 FMS	 compared	 to	 controls	 and	 poor	 sleep	
quality	was	strongly	associated	with	pain	and	fa-
tigue.24
FMS	can	 result	 in	 severe	disability	 and	 loss	of	
function,	making	 daily	 tasks,	 including	 oral	 self-
care,	 difficult	 or	 unmanageable.1,19,25	 Research	
by	Bennett	et	al	 suggests	people	with	FMS	have	










Fatigue,	 inability	 to	 concentrate,	 decreased	 mo-





patients	 reported	 anxiety	 and	 40%	 reported	 de-
pression.19	These	psychological	disturbances	may	
be	 related	 to	 coping	with	 the	 debilitating	 effects	
and	 chronic	 pain	 of	 FMS,	 rather	 than	 a	 primary	
symptom.28	 Cognitive	 deficiency	 in	 people	 with	















































Numbness or tingling Dry eyes





Figure 2: Symptoms of Fibromyalgia Syn-
drome16
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pected	causes	of	FMS	include	abnormalities	in	pain	
pathways,	 as	 well	 as	 genetic	 and	 environmental	
factors.21-23	 Cerebrospinal	 fluid	 substance	 P	 is	 a	
neurotransmitter	released	when	axons	are	stimu-
lated.	 Consistently	 elevated	 in	 people	 with	 FMS,	
this	 causes	 increased	 sensitivity	 and	 enhanced	
awareness	of	pain.23,29	Substance	P	helps	regulate	
the	 responsiveness	 of	 N-methyl-D-aspartate	 re-
ceptors	to	the	neurotransmitter	glutamide,	which	
plays	a	role	 in	central	sensitization	and	temporal	
summation.20,21	 Concentration	 of	 substance	 P	 in	
cerebrospinal	fluid	is	2	to	3	times	higher	in	people	
with	 FMS	 compared	 to	 control	 subjects.23,29 Sub-
stance	P	is	involved	in	transmission	of	pain	infor-
mation	from	the	periphery	to	the	central	nervous	





The	CNS	 is	 the	predominant	 source	of	 pain	 in	
FMS.	 CNS	 sensitization,	 increased	 excitability	 of	
neurons	found	in	the	spinal	cord,	makes	neurons	
more	sensitive	 to	 stimuli.	Central	 sensitization	 is	
characterized	 by	 an	 exaggerated	 pain	 response,	
prolonged	duration	of	pain,	 increased	pain	 inten-
sity	 and	wider	pain	distribution.21 A related phe-
nomenon	to	sensitization	is	temporal	summation,	




suggests	 levels	 of	 temporal	 summation	 from	 re-
petitive	stimulation	in	people	with	FMS	consistent-
ly	exceed	those	of	control	subjects	over	a	range	of	
stimulus	frequencies.31,32 These phenomenon most 
likely	result	in	people	with	FMS	exhibiting	a	lower	





body	 secretes	 cortisol,	 and	during	 chronic	 stress	
the	 body	 continually	 increases	 secretion	 of	 this	




ciency	 is	most	 likely	 culpable	 in	 causing	 non-re-
storative	sleep	for	FMS	patients.22
Research	has	also	linked	abnormal	levels	of	the	
neurotransmitters	 serotonin,	 norepinephrine	 and	
dopamine	with	FMS.2,20,22,23,30,33	Low	serotonin	lev-
els	are	the	most	widely	acknowledged	biochemical	
irregularity	 found	 in	 people	with	 FMS	and	are	of	
particular	interest	due	to	their	affect	on	delta	sleep	
and pain modulation.18,22,23,33-35 Serotonin and nor-
epinephrine play a role in stopping pain response 
by	hindering	pain	pathways.	When	individuals	with	
FMS	 have	 decreased	 levels	 of	 these	 neurotrans-




stress the body tries to restore homeostasis and 
dopamine	 eventually	 becomes	 decreased	 due	 to	
overcompensation	of	the	negative	feedback	loop,	
leading	to	a	hyperalgesic	state.
Both	 genetic	 and	 environmental	 factors	 may	
be	involved	in	the	development	of	FMS.	Research	
suggests	 the	 high	 occurrence	 of	 FMS	 in	 families	
may	be	 attributed	 to	 genetic	 factors.36-38	Women	
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(41%)	 followed	 by	 emotional	 trauma	 (31.3%).19 
Trauma and stress may alter the pain modulatory 
response	in	the	brain,	which	could	contribute	to	the	
enhanced	 pain	 perception.	 Acute	 illness,	 serious	
infection,	 physical	 injury,	 surgery,	 motor	 vehicle	
accidents	and	other	pain	conditions	are	also	com-
monly	 reported	 physical	 stressors.19,33	 Psychoso-
cial	factors,	such	as	a	catastrophic	event	or	abuse	
(emotional,	 physical	 or	 sexual)	 have	 also	 been	
associated	with	onset	of	symptoms.19,33	However,	
research	on	the	relationship	between	physical	and	
emotional	 abuse	 and	 the	 diagnosis	 of	 FMS	 have	
been	inconsistent.40,41	Havilan	et	al	revealed	a	cor-
relation	 between	 both	 sexual	 assault/abuse	 and	
physical	 assault/abuse	 and	 FMS	 diagnosis;	 how-

















and	 cognitive	 behavioral	 therapy.	 Additionally,	







Most	 patients	 with	 FMS	 report	 symptoms	 of	
facial	 pain,	 including	 discomfort	 in	 the	 muscles	
of	 mastication,	 temporomandibular	 joint	 (TMJ),	
neck,	ear	and	jaw.43	A	study	by	Alonso-Blanco	et	













palpation	 of	 the	masticatory	muscles.	 The	 ques-
tionnaire	consisted	of	questions	about	prior	head	
and	 neck	 trauma,	 parafunctional	 habits,	 muscle	
fatigue,	 crepitus	 of	 the	TMJ,	 restricted	mandibu-
lar	movement,	jaw	pain	and	prior	TMD	treatment.	
Results	 revealed	 80%	 of	 patients	 with	 FMS	 had	
masticatory	myofacial	 pain	 and	 TMD.45 This data 
supports	previous	research	that	indicated	the	high	
rate	 of	 involvement	 of	 the	 stomatognathic	 sys-





in	 people	 with	 FMS	 than	 those	without	 the	 syn-







toms	 of	 TMD.	 A	 study	 by	 Pimentel	 et	 al	 investi-
gated	 the	 prevalence	 of	 clinical	 features	 of	 TMD	
in	people	with	FMS.	Forty	women	with	FMS	were	
compared	 to	 40	 healthy	 controls	 using	 the	 Re-
search	Diagnostic	Criteria	for	Temporomandibular	
Disorders	 (RDC/TMD).	 Results	 indicated	 77.5%	












conditions	may	 result	 from	the	alteration	 in	pain	
perception.	 Failure	of	 the	dental	 hygienist	 to	 ac-
knowledge	the	underlying	FMS	diagnosis	may	lead	
to	 lack	of	appropriate	treatment.	Occlusal	splints	
often	 recommended	 for	 patients	 suffering	 from	












FMS.43	 The	 prevalence	 of	 limited	mouth	 opening	
has been reported to be 10 times higher in people 
with	FMS	than	controls	with	the	average	maximum	
voluntary	mouth	opening	 for	 FMS	patients	 at	 41	
mm,	compared	to	44	mm	in	 the	control	group.43 
The	exact	cause	is	unknown,	but	it	is	likely	muscle	
pain	during	 jaw	movements	 contributes	 to	 lower	














mately	 70%	 of	 subjects	 with	 FMS	 experienced	
xerostomia.51	 Only	 27.5%	 of	 FMS	 subjects	 who	
experienced	 xerostomia	 were	 taking	 xerogenic	
medications,	 therefore	 research	 suggests	 a	 high	
prevalence	 of	 xerostomia	 in	 this	 patient	 popula-
tion	even	when	controlling	for	xerostomia-inducing	




Glossodynia	 is	 commonly	 accompanied	 by	 xe-
rostomia	and	dysgeusia	and	is	experienced	by	ap-
proximately	 one-third	 of	 fibromyalgic	 persons.51 
Glossodynia	 may	 represent	 hyperalgesia	 and	 al-
lodynia	 resulting	 from	nervous	 system	 sensitiza-













oral	 manifestation	 of	 FMS	 or	 is	 a	 side	 effect	 of	
medications.	Xerostomia	can	induce	dysgeusia	be-
cause	normal	salivary	flow	and	concentration	are	










oral	manifestations	 of	 FMS	 including	 xerostomia,	
glossodynia	and	dysgeusia	(Figure	5).	When	per-
forming	 an	 extraoral	 exam,	 the	 dental	 hygienist	
should	be	cognizant	of	possible	patient	discomfort	
in	 the	 regions	of	 the	TMJ	and	muscles	 of	masti-
cation.	 Additionally,	 if	 FMS	 is	 not	 diagnosed	 and	
suspected,	 the	 dental	 hygienist	 should	 refer	 the	
patient	for	further	medical	evaluation.17




best	 and	 scheduled	 accordingly.	 Many	 FMS	 pa-
tients	experience	pain	and	stiffness	 that	 is	more	
severe	 in	the	morning;	therefore,	a	 late	morning	
or	 early	 afternoon	 appointment	 may	 work	 best.	
However,	 patients	 with	 FMS	 may	 cancel	 at	 the	
last	 minute	 complaining	 of	 pain,	 fatigue	 or	 lack	
of	 restful	 sleep.	 Additionally,	 FMS	 patients	 may	
not be able to tolerate long appointments due to 
jaw	tiredness	and	pain.	If	possible,	offer	to	break	
up	 the	patient’s	 treatment	plan	 to	accommodate	
shorter	appointments.	To	promote	efficiency	dur-
ing	 the	 appointment,	 a	 dental	 hygiene	 assistant	
and	4-handed	dentistry	is	recommended.	Patients	
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A	 stress-free	 treatment	 environment	 is	 ideal	
since	stress	can	exacerbate	the	pain	response	 in	
FMS	patients.18,19 Strategies to help manage stress 
during	the	appointment	include	developing	a	trust-
ing	relationship	between	the	patient	and	the	prac-








Preventing	oral	 infection	 is	 important	 since	 in-














ened	 pain	 sensitivity	 and	 fatigue,	 modifications	
may	be	necessary	to	ensure	patient	comfort	and	
adequate	pain	management.	Both	topical	and	local	
anesthetic	 agents	 are	 recommended	 to	 manage	
discomfort	 during	 scaling	 and	 root	 debridement.	
Anesthetic	agents	with	vasoconstrictors	should	be	
avoided	 for	patients	 taking	amitriptyline	 (Elavil®,	
AstraZeneca,	London,	UK),	venlafaxine	(Effexor®,	
Wyeth	 Pharmaceuticals,	 Madison,	 NJ)	 or	 dulox-
etine	 because	 they	 may	 create	 a	 hypertensive	




ing	 dental	 hygiene	 care,	 practitioners	 will	 find	 a	
mouth	prop	or	bite	block	most	effective	as	this	can	
provide	additional	support	for	those	who	have	lim-




in	 the	 jaw	 region	 (unless	 heat	 exacerbates	 their	
symptoms)	and	use	analgesics	 such	as	 tramadol	
(Ultram®;	 Janssen	 Pharmapeuticals,	 Titusville,	
NJ)	or	muscle	 relaxants	 such	as	 cyclobenzaprine	
(Flexiril®;	McNeil	Consumer	and	Specialty	Pharma-
ceuticals,	 Fort	 Washington,	 Penn)	 and	 tizanidine	
(Zanaflex®;	 Acorda	 Therapeutics,	 Ardsley,	 NY).17 




Patients	 with	 FMS	 are	 often	 hypersensitive	
to	 stimuli	 such	 as	 noise,	 heat,	 cold,	 touch	 and	
light.1,21,23	These	normally	non-painful	stimuli	may	
produce	pain	for	people	with	FMS.	Therefore,	pa-
tients	 should	 be	 consulted	 about	 the	 impact	 of	
extraneous	 noise,	 such	 as	 background	 music,	
televisions	 and	powered	 scalers	 so	 these	 can	be	
eliminated	 or	 minimized	 if	 bothersome.	 A	 blan-
ket	or	warm	neck	roll	should	be	readily	available	




and	 neck.	 Additionally,	 since	 some	 FMS	 patients	
experience	hypersensitivity	to	light,	oral	care	pro-
fessionals	 should	be	 conscientious	of	not	 shining	
the	 dental	 light	 in	 the	 patient’s	 eyes	 and	 tinted	
eyewear	should	be	provided.
Patient Education












Due	 to	 the	 debilitating	 effects	 of	 FMS	and	 co-
morbidities,	patients	may	have	difficulty	perform-
ing	 oral	 self-care.	 Extremities	 of	 FMS	 patients	
often	 feel	 swollen,	 with	 upper	 extremities	 more	
impacted	 than	 lower	 extremities;	 therefore,	 oral	
self-care	may	 be	 negatively	 affected.61 Addition-
ally,	FMS	often	co-occurs	(up	to	25	to	65%)	with	
other	 rheumatic	 conditions,	 and	 as	 a	 result	 of	
these	 conditions,	 some	 patients	may	 experience	








devices	or	the	patient	 fatigues	easily.63 For some 
patients,	 modifying	 the	 toothbrush	 by	 extend-
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Conclusion
FMS	 is	 a	 common	 disorder	 that	 encompasses	
symptoms	of	chronic,	widespread	musculoskeletal	
pain,	 fatigue,	 cognitive	 deficiency	 and	 sleep	 dis-
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ing or enlarging the handle may also be helpful.63 
These	modifications	can	also	be	performed	on	floss	










prevalence	 of	 cognitive	 issues	 resulting	 in	 de-
creased	mental	alertness	and	memory	(fibro	fog),	
patients	 may	 benefit	 from	 written	 self-care	 in-
structions	and	educational	materials	they	can	take	
home	to	reinforce	important	concepts.
Patients	 should	 be	 educated	 on	 the	 difference	
between	 the	 chronic,	 widespread	 FMS	 pain	 and	
acute	pain	 from	an	oral	disease	or	 infection.	Pa-
tients may attribute dental pain to symptoms of 
FMS	and	not	seek	immediate	care,	resulting	in	mi-
nor	dental	disease	escalating	to	major.	Therefore,	




treatment	 is	 required,	which	may	 be	 difficult	 for	
the	patient	to	withstand.
Dental	 hygienists	 should	 encourage	 FMS	 pa-
tients	 with	 xerostomia	 to	 take	 an	 active	 role	 in	
the	management	 of	 their	 symptoms	 to	minimize	
risk	of	adverse	oral	effects.	Strategies	to	help	al-
leviate	xerostomia	include	using	saliva	substitutes	
and	 sialogogues,	 and	 avoiding	 alcohol	 and	 caf-
feine	consumption.	Saliva	substitutes	can	be	used	
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